Puriman is committed to providing integrated, end-to-end drug discovery and production services to the global biomedical industry. Through the "CRDMO" business model, we continue to lower the threshold of customer research and development, provide customers with efficient research and development services, and bring more breakthrough treatment solutions to patients. Puriman services cover chemical drug development and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production.
As a leading enterprise in the construction of CDMO platform, Puriman is committed to lowering the threshold of customer research and development, improving the efficiency of customer research and development, and providing customers with professional technical and service support. We have rich experience and strength in many fields such as chemical drug development and production, biological research, preclinical testing and clinical trial research and development, cell and gene therapy research and development, testing and production, and can provide customers with a full range of services.
Through continuous technological innovation and research and development investment, we continue to expand our technical strength and innovation ability. The company has the world's leading research and development platform and strong talent team, committed to the development of safer and more effective drugs and treatments. Puriman pays attention to quality assurance, through the establishment of a sound quality management system and strict drug quality and safety measures to ensure that the quality of products is stable and in line with international standards.
As a world-renowned pharmaceutical company, we will continue to promote the development of the healthcare industry, provide safer and more effective treatments and drugs for patients, provide more efficient and professional services for customers, and help customers accelerate the process of drug development and commercialization.
Hong Kong Puriman Company was founded in 2023.
Henan Purui Pharmaceutical Co., Ltd. was established in 2021.
Henan Purui Medicine Co., Ltd. was established in 2018.
Shanghai Xinren Chinese Medicine Pharmaceutical Co., Ltd. was established.
Quick navigation
Company profile Service(CRDMSO) Products News Join Us ContactSales hotline
Miss Fang: +86-15618978166 (API, Intermediates)
Gao Yunping: +86-15516713896 (API)
Manager Liu: +86-13193611579 (API)
Email: elaine@puruipharm.com (Miss Fang)
Follow us
Copyright(C)2024,Henan Purui Pharmaceutical Co., Ltd. All Rights Reserved.
Supported by ChemNet ChinaChemNet Toocle 31fabu Copyright Notice 備案號:豫ICP備2024056222號-1 【網(wǎng)站后臺】